8x8 Inc vs Medtronic PLC — how do they compare? 8x8 Inc trades at $2.04 (market cap $309.09M), while Medtronic PLC trades at $90.09 (market cap $116.07B). The key difference: Medtronic PLC is far larger — about 375.5× 8x8 Inc's market cap, and Medtronic PLC pays a 3.18% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals.
| EGHT | MDT | |
|---|---|---|
Market Cap | $309.09M | $116.07B |
Sector | Technology | Health |
52-Week High | $2.76 | $105.35 |
52-Week Low | $1.59 | $73.75 |
Enterprise Value | $576.02M | $134.82B |
Dividend Yield | — | 3.18% |
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.06, down 8.04% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with five consecutive quarters of revenue growth and consistent earnings beats, though profitability remains thin with a 0.64% net margin. Recent AI product expansions and partner program launches signal strategic growth initiatives. Analyst consensus targets $3.13, representing 52% upside potential from current levels.
EGHT presents a compelling risk-reward profile with significant analyst upside but faces execution risks in a competitive communications sector. The transition to profitability in 2026 forecasts and strong institutional support offset near-term volatility concerns. Key risks include high debt levels and margin pressure, while AI adoption growth and consistent earnings outperformance provide catalysts for valuation expansion.
Medtronic (MDT) trades at $89.41, up 2.58% on the day, reflecting positive momentum. The stock exhibits bullish technical signals with strong moving average support and a consensus analyst price target of $98.75. Fundamentally, the company reported revenue of $33.54B for 2025 with a net income margin of 13.2%, and has consistently beaten EPS estimates in recent quarters. Recent news highlights institutional acquisitions and positive developments in medical technology platforms.
The outlook for MDT is positive, driven by earnings beats, robust cash flow, and growth in cardiac and robotic surgery segments. Key opportunities include undervaluation relative to analyst targets and dividend stability. Risks involve rising debt levels and competitive pressures in the medtech sector. The stock presents a compelling case for growth-oriented income investors.
Trailing returns across standard periods
Latest headlines on both assets
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →